PerpEquities

Top analysts on stock perps · Analyst

Patrick Trucchio (H.C. Wainwright): analyst track record on stock perps

Patrick Trucchio of H.C. Wainwright on companies with stock perpetual futures: star rating, success rate, price-target accuracy, current calls and the measured perp reaction after each rating.

Stars5★
Success55%
Excess return+36.7%
rank#98
Ratings499
ratings on stock perps101

Track record

TipRanks data via FMP

After buy calls: not enough measured cases yet

Current calls on stock perps

StockCallTargetvs last closeDate
$ALNY Alnylam Pharmaceuticals, Inc.Buy · Reiterated$455Sep 21, 2026
$ARWR Arrowhead Pharmaceuticals, Inc.Buy · Maintained$120Sep 21, 2026

Recent ratings

  • Sep 21, 2026 $ARWR: Maintained · Buy · $120 · article
  • Sep 21, 2026 $ALNY: Reiterated · Buy · $455 · article
  • Sep 2, 2026 $ALNY: Reiterated · Buy · $455 · article
  • Sep 1, 2026 $ARWR: Reiterated · Buy · $120 · article
  • Aug 7, 2026 $ARWR: Reiterated · Buy · $120 · article
  • Aug 4, 2026 $ALNY: Reiterated · Buy · $455 · article
  • Jul 30, 2026 $ALNY: Reiterated · Buy · $485 · article
  • Jul 27, 2026 $ARWR: Reiterated · Buy · $115 · article
  • Jul 22, 2026 $ARWR: Reiterated · Buy · $100 · article
  • Jul 13, 2026 $ALNY: Reiterated · Buy · $485 · article
  • Jul 6, 2026 $ARWR: Reiterated · Buy · $100 · article
  • Jul 6, 2026 $ALNY: Reiterated · Buy · $470 · article
  • Jul 1, 2026 $ARWR: Reiterated · Buy · $100 · article
  • Jun 29, 2026 $ALNY: Reiterated · Buy · $470 · article
  • Jun 25, 2026 $ARWR: Reiterated · Buy · $100 · article
  • Jun 5, 2026 $ALNY: Reiterated · Buy · $510 · article
  • May 22, 2026 $ARWR: Reiterated · Buy · $100 · article
  • May 5, 2026 $ALNY: Reiterated · Buy · $510 · article
  • Apr 29, 2026 $ARWR: Reiterated · Buy · $100 · article
  • Apr 29, 2026 $ALNY: Reiterated · Buy · $510 · article

Patrick Trucchio5★ · 55% success · +36.7% excess return · TipRanks data via FMP · Source headlines via TheFly/StreetInsider (FMP). Reaction = venue-median perp move after our detection — an observation, not investment advice.